The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 5, issue 4, 2004

Using diagnosis-related groups pp. 287-289

M. Lungen, B. Dredge, A. Rose, C. Roebuck, E. Plamper and K. Lauterbach

Re-scaling social preference data: implications for modelling pp. 290-298

Irina Cleemput, Paul Kind and Katrien Kesteloot

Willingness to pay for dental fear treatment pp. 299-308

Bente Halvorsen and Tiril Willumsen

What reimbursement for coronary revascularization with drug-eluting stents? pp. 309-316

Rosanna Tarricone, Monia Marchetti, Mark Lamotte, Lieven Annemans and Peter Jong

A method for cross-sector priority setting pp. 317-323

Tugrul Temel

Drug price regulation under consumer moral hazard pp. 324-329

Stefan Felder

Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy pp. 330-334

Iva Krulichova, Sara Gamba, Elena Ricci and Livio Garattini

A note on the impact of hours worked on mortality in OECD countries pp. 335-340

Edvard Johansson

The high cost of medicines in Ireland pp. 341-344

Lesley Tilson, Bernadette McGowan, Kathleen Bennett and Michael Barry

Approval times and the safety of new pharmaceuticals pp. 345-350

Niklas Rudholm

Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden pp. 351-356

Joakim Ramsberg, Stefan Odeberg, Andreas Engström and Douglas Lundin

Data envelopment analysis based bonus payments pp. 357-364

Stefan Felder and Horst Schmitt

Exponential health utility pp. 365-367

Lars Peter Østerdal

Volume 5, issue 3, 2004

Discrete choice experiments in health economics pp. 199-202

Stirling Bryan and Paul Dolan

Side effects of generic competition? pp. 203-208

Jörgen Hellström and Niklas Rudholm

Estimating rural households’ willingness to pay for health insurance pp. 209-215

Ali Asgary, Ken Willis, Ali Taghvaei and Mojtaba Rafeian

Measuring and comparing the (in)efficiency of German and Swiss hospitals pp. 216-226

Lukas Steinmann, Gunnar Dittrich, Alexander Karmann and Peter Zweifel

Costs and consequences of botulinum toxin type A use pp. 227-235

Francis Ruiz, Julian Guest, Almut Lehmann, Alison Davie, Karen Güttler, Olaf Schlüter and Götz Dreiss

Economics and health promotion pp. 236-242

Luke Connelly

The cost structure of lung tuberculosis in Germany pp. 243-251

Roland Diel, Bernhard Rappenhöner and Tom Schaberg

Financing of health care services in Hungary pp. 252-258

Imre Boncz, Júlia Nagy, Andor Sebestyén and László Kőrösi

Health care provider payment mechanisms in the new EU members of Central Europe and the Baltic states pp. 259-262

Agota Szende and Zsolt Mogyorosy

Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies pp. 263-269

Hindrik Vondeling and Peter Iversen

Costs of treatment of colorectal cancer in different settings in Germany pp. 270-273

Klaus Hieke, Ulrich Kleeberg, Martina Stauch and Axel Grothey

Out-patient drug policy by clinical assessment rather than financial constraints? pp. 274-277

Marja Pronk and Gouke Bonsel

A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain pp. 278-284

Juan Gómez-Gerique, Roman Casciano, Lee Stern and Javier Rejas

Volume 5, issue 2, 2004

The risk-adjusted vision beyond casemix (DRG) funding in Australia pp. 95-109

Kathryn Antioch and Michael Walsh

Pricing of pharmaceuticals pp. 110-115

Mark Nuijten and Joszef Kosa

The risk-adjusted vision beyond casemix (DRG) funding in Australia pp. 115-115

Kathryn Antioch and Michael Walsh

Genetic screening, health care and the insurance industry pp. 116-121

Diego Ossa and Adrian Towse

Price-cost margin in the pharmaceutical industry pp. 122-128

Ismo Linnosmaa, Raine Hermans and Taru Hallinen

Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease pp. 129-135

Thomas Hoffmann and Helmut Brunner

Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients pp. 136-142

Janne Martikainen, Hannu Valtonen and Tuula Pirttilä

Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine pp. 143-149

Francis Fagnani, Camille Fur, Isabelle Durand and Michel Gibergy

An empirical analysis of the demand for physician services across the European Union pp. 150-165

Sergi Jimenez-Martin, Jose Labeaga and Maite Martinez-Granado

Economic growth, longevity and the epidemiological transition pp. 166-174

Olivier Morand

Dynamic competition in pharmaceuticals pp. 175-182

Laura Magazzini, Fabio Pammolli and Massimo Riccaboni

The European Network of Health Economic Evaluation Databases (EURO NHEED) Project pp. 183-187

John Nixon, Philippe Ulmann, Julie Glanville, Stéphanie Boulenger, Michael Drummond and Gérard Pouvourville

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK pp. 188-189

Nick Bansback, Sue Ward and Jon Karnon

Pricing and reimbursement of drugs in Ireland pp. 190-194

Michael Barry, Lesley Tilson and Máirín Ryan

Volume 5, issue 1, 2004

A review of European studies on the economic burden of brain diseases pp. s4-s4

Bengt Jönsson and Jes Olesen

Economic evidence in addiction: a review pp. s5-s12

Patrik Andlin-Sobocki

Evaluating the effect of care programs for elderly persons with dementia on caregiver’s well-being pp. 6-14

Agnès Gramain and Laëtitia Malavolti

Economic evidence in affective disorders: a review pp. s12-s20

Mickael Löthgren

Direct medical costs unequivocally related to diabetes in Italian specialized centers pp. 15-21

Livio Garattini, Francesca Chiaffarino, Dante Cornago, Carlo Coscelli and Fabio Parazzini

Economic evidence in anxiety disorders: a review pp. s20-s25

Mickael Löthgren

Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments pp. 22-27

Livio Garattini, Emanuela Castelnuovo, Paolo Lanzetta, Cecilia Viscarra, Elena Ricci and Fabio Parazzini

Economic evidence in brain tumour: a review pp. s25-s30

Mattias Ekman

Priority setting for pharmaceuticals pp. 28-35

Anders Anell

Economic evidence in dementia: a review pp. s30-s35

Linus Jönsson

Economic evidence in epilepsy: a review pp. s36-s42

Mattias Ekman and Lars Forsgren

Economic valuation of informal care pp. 36-45

Bernard van den Berg, Werner Brouwer and Marc Koopmanschap

Economic evidence in migraine and other headaches: a review pp. s43-s54

Jenny Berg

An exponential representation of health state utility pp. 45-45

Michael Happich and Axel Muehlbacher

The burden of varicella in Germany pp. 46-53

Kurt Banz, Stefan Wagenpfeil, Albrecht Neiss, Thomas Hammerschmidt and Peter Wutzler

Economic evidence in multiple sclerosis: a review pp. s54-s62

Gisela Kobelt

Do costs of varicella justify routine infant vaccination? pp. 54-57

M. Postma, J. Bos, R. Welte, R. Groot, W. Luytjes, H. Rümke and P. Beutels

Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy pp. 58-63

Franz Hessel, Christoph Wegner, Johannes Müller, Christina Glaveris and Juergen Wasem

Economic evidence in parkinson’s disease: a review pp. s63-s66

Peter Lindgren

Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards pp. 64-69

Jörg Ruof, Jan Hülsemann, Thomas Mittendorf, Silke Handelmann, Rick Aultman, J. Schulenburg, Henning Zeidler and Sonja Merkesdal

Economic evidence in psychotic disorders: a review pp. s67-s74

Mickael Löthgren

Economic burden of head and neck cancer pp. 70-80

Jennifer Lee, Marco Turini, Marc Botteman, Jennifer Stephens and Chris Pashos

Economic evidence in stroke: a review pp. s74-s83

Mattias Ekman

Chained time trade-off and standard gamble methods pp. 81-86

Paul McNamee, Sharon Glendinning, Jonathan Shenfine, Nick Steen, S. Griffin and John Bond

Economic evidence in trauma: a review pp. s84-s91

Jenny Berg